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Attention-deﬁ cit hyperactivity disorder 2 
Adult attention-deﬁ cit hyperactivity disorder: 
key conceptual issues
Philip Asherson, Jan Buitelaar, Stephen V Faraone, Luis A Rohde
For many years, attention-deﬁ cit hyperactivity disorder (ADHD) was thought to be a childhood-onset disorder that 
has a limited eﬀ ect on adult psychopathology. However, the symptoms and impairments that deﬁ ne ADHD often 
aﬀ ect the adult population, with similar responses to drugs such as methylphenidate, dexamphetamine, and 
atomoxetine, and psychosocial interventions, to those seen in children and adolescents. As a result, awareness of 
ADHD in adults has rapidly increased and new clinical practice has emerged across the world. Despite this progress, 
treatment of adult ADHD in Europe and many other regions of the world is not yet common practice, and diagnostic 
services are often unavailable or restricted to a few specialist centres. This situation is remarkable given the strong 
evidence base for safe and eﬀ ective treatments. Here we address some of the key conceptual issues surrounding the 
diagnosis of ADHD relevant to practising health-care professionals working with adult populations. We conclude 
that ADHD should be recognised in the same way as other common adult mental health disorders, and that failure 
to recognise and treat ADHD is detrimental to the wellbeing of many patients seeking help for common mental 
health problems.
Attention-deﬁ cit hyperactivity disorder (ADHD) 
as a lifespan disorder
ADHD is classiﬁ ed in the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental 
Disorders (5th edition; DSM-5) as a childhood-onset 
neurodevelopmental disorder, deﬁ ned by the presence of 
developmentally inappropriate and impairing levels of 
inattention, hyperactivity, and impulsivity.1 Epidemio-
logical surveys ﬁ nd that 5–6% of children meet DSM-IV 
criteria for ADHD,2,3 with a slightly higher prevalence 
expected when DSM-5 criteria are applied.4 Meta-analysis 
of follow-up studies of children with ADHD found that 
15% of children retained the full diagnostic criteria by the 
age of 25 years, with a further 50% of those meeting 
subthreshold criteria with persistence of ADHD 
symptoms causing continued impairments.5 Another 
study using a survey approach of 629 adults in ten 
countries found that 50% of children with ADHD 
continued to meet diagnostic criteria for ADHD as 
adults.6 More recently, two follow-up studies of children 
from child mental health clinics in southeast England 
and the Netherlands, meeting DSM-IV combined-type 
(inatten tion and hyperactivity-impulsivity) criteria for 
ADHD, found far higher persistence rates of ADHD in 
young adulthood, in the region of 80%.7,8 The increased 
prevalence of persistence in these studies might be 
related to the focus on combined-type cases, greater 
severity of ADHD in patients treated in European child 
mental health services, and the use of informant data 
when establishing the diagnosis at follow-up.7,9,10
These ﬁ ndings are largely consistent with the estimated 
prevalence of ADHD in adults, which ranges from 2·5% 
to 3·4% in meta-analytic studies of population surveys.11,12 
However, all adults meeting diagnostic criteria for ADHD 
did not necessarily meet full ADHD criteria during their 
childhood. The present DSM-5 criteria allow for this 
possibility by stating that the criterion for age of onset is 
that “several inattentive or hyperactive-impulsive 
symptoms were present prior to age 12 years”.1 This 
criterion allows children with subthreshold levels of 
ADHD symptoms and no impairment to meet diagnostic 
criteria for ADHD later in life and raises the possibility 
that the full diagnosis of ADHD might emerge at 
diﬀ erent developmental stages. The traditional 
explanation for this is that children with high intelligence 
quotients (IQs) or well developed executive function 
skills, who are well supported by structured home and 
school settings, might make use of so-called external 
scaﬀ olding that facilitates compen satory behavioural 
mechanisms. Once such external scaﬀ olding is removed, 
when leaving home and school for example, the full 
syndrome could emerge. Interestingly, this account of 
later-onset ADHD shows the interdependence of the 
association between symptoms and impairments of the 
disorder. An alternative hypothesis suggests that ADHD 
symptom expression depends on the eﬃ  ciency of 
executive control processes.13 Poor maturation of cortical 
control during the adolescent years might lead to later-
emerging ADHD in some cases. Findings suggest that a 
late-onset ADHD-like syndrome might emerge, even in 
the absence of substantial childhood symptoms, perhaps 
reﬂ ecting an acquired syndrome with a diﬀ erent set of 
causal risk factors.10,14
Nevertheless, for the vast majority of patients diagnosed 
with ADHD in clinical settings during adulthood, there is 
a clear account of ADHD from childhood. Therefore, to 
provide an understanding of the developmental trajectory 
of the disorder, the way it presents in adults, and its eﬀ ect 
on adult mental health is of considerable interest. Across 
many regions of the world, ADHD is only just emerging as 
www.thelancet.com/psychiatry   Vol 3   June 2016 569
Series
a disorder that is diagnosed and treated by adult mental 
health services, despite the high prevalence of adult ADHD 
and established links to psychosocial, functional, and 
mental health problems. Even more striking are the very 
high rates of undiagnosed or untreated ADHD within 
adult clinical and forensic services. Several studies point to 
high rates of undiagnosed ADHD in prisons 
(roughly 26%),15 addiction units (roughly 12%),16,17 and 
general adult mental health services (roughly 16%).18 Rates 
of adult ADHD in primary care are less well established, 
but it is clear that a substantial group of patients presenting 
with non-psychotic long-term mental health problems 
meet diagnostic criteria for ADHD.19
The diagnostic construct of ADHD
For many years, researchers have argued that most 
mental health disorders reﬂ ect the extreme and impairing 
tail of one or more continuously distributed traits. Present 
research strategies, such as the Research Domain Criteria 
(RDoC), increasingly focus on delineating the under lying 
neurobiological substrates that underpin dimen sions of 
psychopathology.20 Among these, ADHD is one of the 
best examples in which no point of rarity can be found in 
the distribution of ADHD symptoms and impairments 
seen throughout the population.21 Symptoms of ADHD 
cluster together into two key dimensions of inattention 
and hyperactivity-impulsivity, are reliably measured, and 
are strong predictors of functional impairments, but they 
reﬂ ect continuous traits rather than a categorical 
disorder.22,23 Of particular relevance to adult ADHD is the 
relative persistence of inattention and improvements in 
hyperactive-impulsive symptoms during development, so 
that many patients who had the combined type 
presentation of ADHD as children present with 
predominantly inattentive symptoms as adults.7,23,24
Many studies support the continuous nature of ADHD 
symptoms, although most of this work has been done in 
children rather than in adults.21,25–27 These studies report 
the following: estimates of heritability are similar for 
continuous ratings of ADHD symptoms in the general 
population and the categorical disorder (around 
70–80%);28 group heritability estimates show that genetic 
risk for the disorder is shared with genetic risk for the 
continuous trait;26,29 polygenic risk scores for ADHD 
predict ADHD trait scores in general population 
samples;30 the association of ADHD with cognitive 
performance deﬁ cits is similar for the clinical disorder 
and ADHD symptom scores in general population 
samples;25,31 and risk of impairment shows a linear 
relationship with severity of ADHD symptoms in 
population samples.27,32 As a result, the boundary 
between patients with and without a clinically signiﬁ cant 
disorder is deﬁ ned by the presence of clinically 
signiﬁ cant impairment. Although the presence of 
impairment is a deﬁ ning characteristic of many adult 
mental health disorders, such as anxiety and depression, 
the inclusion of impairment criteria is particularly 
important for trait-like disorders such as ADHD and 
personality disorders, where the symptoms do not reﬂ ect 
a change from the premorbid state. Thus, the diagnosis 
of ADHD is to some extent dependent on perceptions of 
what amounts to clinically signiﬁ cant impairment. 
However, the symptoms of inattention and hyperactivity-
impulsivity are known to reﬂ ect individual diﬀ erences in 
brain structure and function that largely derive from 
genetic inﬂ uences,33 and the associated impairments are 
often severe.34
In clinical practice, the continuous nature of ADHD 
should not present diagnostic diﬃ  culties in moderate-to-
severe cases, but might cause diﬃ  culties in mild cases 
with more subtle forms of impairment. Careful attention 
is needed to assess the eﬀ ect of ADHD symptoms on 
impairment and quality of life, including an 
understanding of the broader range of problems linked 
to ADHD (eg, executive function [self-regulation] 
impairments, sleep problems, irritability, and internal 
restlessness), in addition to functional impairments such 
as traﬃ  c accidents and occupational under achievement. 
Therefore, some individuals, who seem to function well, 
might nevertheless suﬀ er from a substantial mental 
health problem related to ADHD. When assessing 
impair ments, it is important to take into account that 
even minor levels of symptoms can cause considerable 
distress to individuals because of the chronic and 
persistent nature of ADHD symptoms, which are 
experienced by people with ADHD on a daily basis.
Rater eﬀ ects and measurement of ADHD 
symptoms
One factor complicating the assessment of ADHD is the 
change in informant during development. Throughout 
most of childhood and early adolescence, the primary 
informants for diagnostic information are parents and 
teachers, who report mainly on the basis of observed 
behaviours. For this reason, the ADHD symptoms listed 
in DSM-IV/5 and International Classiﬁ cation of Diseases 
(10th edition; ICD-10) are largely descriptions of observed 
behaviours rather than subjective reports of mental state 
changes. Rater eﬀ ects turn out to be important in the 
assessment of ADHD.9,35 Several pieces of evidence 
indicate that informant report (eg, parents) is more 
accurate than self-report, with adults tending to under-
rate their symptoms. Quantitative genetic studies using 
ADHD self-report scales in general population twin 
samples ﬁ nd far higher heritability for parent report 
(around 70–80%) than for self-report (around 35–50%).36 
Although these ﬁ gures might be related to rater bias in 
parents inﬂ ating heritability estimates, this seems 
unlikely when converging evidence is considered. For 
example, high heritability estimates based on diagnosed 
cases of adult ADHD (using multiple sources of 
information) are similar to those of childhood cases of 
ADHD.28 Rater eﬀ ects were also seen in a 6-year 
follow-up study of children with combined -type ADHD. 
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Higher prevalence of persistent ADHD was found when 
the diagnosis was based on parent report than on self-
report. Moreover, parent-reported ADHD, but not self-
reported ADHD was subsequently validated by the 
association with cognitive performance measures on 
sustained attention and inhibitory control tasks.35
An attempt to improve the criteria by including more 
age-appropriate descriptions has been included in DSM-5 
(panel 1). These descriptions of ADHD symptoms are 
nevertheless largely behavioural and might still be subject 
to rater eﬀ ects. One alternative that could lead to more 
accurate self-ratings of ADHD is to focus on subjective 
accounts of mental state phenomena, in the same way as 
individuals might report feeling depressed, experiencing a 
panic attack, or hearing a voice. Surprisingly, there have 
been only limited attempts to pursue such a 
phenomenological approach in ADHD. Another option is 
to develop more objective cognitive or neuroimaging tests 
for ADHD. A further approach is to provide a more 
detailed account of the types of behavioural problems 
reported by adults with ADHD. As a result, providing 
alternative accounts of adult ADHD that might provide 
more objective measures of ADHD symptoms, or a better 
understanding of the mental state changes and behavioural 
problems experienced by adults is of considerable interest.
Cognitive and neuroimaging markers of ADHD
Cognitive performance measures of attention and 
impulsivity have been suggested in neurocognitive 
studies as markers of ADHD symptoms, with several 
companies marketing diﬀ erent versions of continuous 
performance tasks (sustained attention and inhibitory 
control tasks that measure errors of omission, 
commission, and reaction time). The assumption made 
is that omission errors reﬂ ect behavioural inattention, 
commission errors reﬂ ect behavioural impulsivity, and 
reaction time variability reﬂ ects ﬂ uctuations in 
attention. An additional measure has been the use of 
actigraph data to capture overactivity during 
experimental tasks or in daily life. Of these measures, 
activity level rather than cognitive performance might 
provide the best prediction of adult ADHD.7,37,38 
Preliminary studies show reasonable separation of cases 
from healthy controls when all parameters are combined 
(sensitivity and speciﬁ city around 85–90%), but poor 
separation of cases from clinical controls,37,38 due to 
heterogeneity and absence of speciﬁ city of the cognitive 
impairments to ADHD. Persistence of the disorder 
from childhood into adulthood might also be predicted 
by objectively measured activity level but not by 
cognitive performance measures.7
Cognitive performance measures have also been 
investigated in children as predictors of the clinical 
response to methylphenidate. Although drug eﬀ ects on 
cognitive performance measures are observed, these do 
not seem to covary with the clinical response, suggesting 
that the test variables cannot be considered proxies for 
ADHD symptoms.39,40 Another approach has been the 
use of electroencephalography as a cost-eﬀ ective measure 
of neuronal activity, in particular the use of the theta-beta 
ratio (TBR) as an aid to diagnosis. Unfortunately, 
available publications and meta-analyses were unable to 
ﬁ nd consistent case-control diﬀ erences, indicating that 
TBR has limited value as a diagnostic tool.41
Further research is clearly needed to identify clinically 
useful cognitive and neural biomarkers of ADHD, 
although these approaches are hampered by the marked 
heterogeneity of the cognitive and neural deﬁ cits seen in 
adult ADHD. This obstacle complicates the identiﬁ cation 
of cognitive or neural measures, although it is feasible 
that such approaches will identify more homogeneous 
subtypes of ADHD. Never theless, promising ﬁ ndings 
are beginning to emerge from neuroimaging studies, 
showing the increased sensitivity of measures of neural 
activity compared with cognitive performance measures.33 
Examples include consistent evidence of reduced 
activation of the ventral striatum when anticipating a 
reward42 and deﬁ cits in deactivation of the default mode 
network when engaging in cognitive tasks.43
One particularly interesting approach is to look for 
markers of clinical change which covary with the clinical 
disorder, either during the treatment response to drugs 
or during follow-up studies. An investigation of the 
covariation of ADHD symptoms with regional brain 
activation patterns during a functional MRI (fMRI) 
go/no-go paradigm (assessing inhibitory processes) 
during treatment with methylphenidate and atomoxetine 
found that ADHD symptom improvement was associated 
with reductions in bilateral motor cortex activation for 
both treatments. Symptom improvements were also 
Panel 1: Age-appropriate attention-deﬁ cit hyperactivity 
disorder symptoms (DSM-5)
• Mind seems elsewhere, even in the absence of any 
obvious distraction
• Starts tasks, but quickly loses focus and is easily side-tracked
• Fails to ﬁ nish tasks in the workplace
• Reporting unrelated thoughts
• Problems returning calls, paying bills, keeping appointments
• Diﬃ  culty in managing sequential tasks; diﬃ  culty in 
keeping materials and belongings in order; messy, 
disorganised work
• Poor time management
• Tends to fail to meet deadlines
• Feeling restless
• Unable or uncomfortable being still for an extended time, 
such as in restaurants or meetings
• Might be perceived by others as being restless and diﬃ  cult 
to keep up with
• Butts into conversations or activities, might start using 
other people’s belongings without permission, might 
intrude into or take over what others are doing 
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diﬀ erentially related to gains in task-related activations 
for atomoxetine and reductions for methylphenidate in 
the right inferior frontal gyrus, left anterior cingulate, 
and bilateral posterior cingulate cortex.44 Although these 
preliminary ﬁ ndings are proof-of-principle at this stage, 
they do show the value of outcome studies in 
identiﬁ cation of neural biomarkers for ADHD symptoms.
Characteristic features of ADHD that support 
the diagnosis
Focus on the mental state of adult patients with ADHD 
has been of more immediate clinical value than the use of 
cognitive or neuroimaging data. Symptoms such as 
feeling physically restless, emotional dysregulation, 
excessive mind wandering, and sleep-onset insomnia are 
all clinically relevant symptoms that are commonly seen 
in adult ADHD. Surprisingly, these symptoms are not 
well studied in ADHD despite their potential value in 
clinical practice.
Sleep problems
Disturbed sleep is reported by 70% or more of adults 
with ADHD. In particular, diurnal rhythm abnormalities 
have been identiﬁ ed that are associated with sleep-onset 
insomnia.45 Although not formally a criterion for ADHD, 
the presence of sleep-onset problems associated with 
reports of ADHD symptoms can be used to support the 
diagnosis of ADHD. For example, many adults with 
ADHD complain that they are too physically and mentally 
restless to fall asleep. We should also be alert to the 
possibility that sleep apnoea might cause symptoms of 
ADHD.46
Emotional dysregulation
Another associated feature of ADHD, recommended by 
DSM-5 as supporting the diagnosis, is emotional 
dysregulation including low frustration tolerance, 
irritability, and mood lability.1 Several reports highlight 
the very high frequency of emotional dysregulation in 
adult ADHD with either rating scale measures47–49 or 
experience sampling of mood states throughout the day.50 
These studies show that emotional dysregulation is 
present in non-comorbid cases of adult ADHD and 
predicts impairment beyond that explained by inattention 
and hyperactivity-impulsivity.47,48,50 A common set of 
genes inﬂ uence emotional dysregulation and core 
ADHD symptoms in children.51 Importantly, emotional 
dysregulation in adults with ADHD responds to 
stimulants and atomoxetine with a similar eﬀ ect size as 
the core ADHD symptoms of inattention and 
hyperactivity-impulsivity.52–55 Although these ﬁ ndings 
suggest that symptoms of emotional dysregulation 
should be viewed as a core component of ADHD, because 
they frequently occur in other disorders (eg, anxiety, 
mood disorders, substance misuse, and personality 
disorders) they are not used as primary diagnostic criteria 
for the classiﬁ cation of ADHD.
Excessive mind-wandering
Another common feature of adult ADHD is excessive 
mind-wandering, also referred to as mental 
restlessness.56–58 In DSM-5, mind-wandering is brieﬂ y 
mentioned as the occurrence of unrelated thoughts. 
Mind-wandering occurs when a person’s mind drifts 
away from a task and focuses on internal thoughts and 
images that are unrelated to the task or situation at hand. 
Although mind-wandering is a universal experience, 
some forms of mind-wandering are detrimental because 
they arise spontaneously and interfere with task 
performance. Interestingly, mind-wandering is 
associated with performance deﬁ cits overlapping with 
those seen in ADHD, including educational performance, 
driving accidents, and cognitive performance errors such 
as commission errors and reaction time variability on 
sustained attention and inhibition tasks.59 Mind-
wandering is also strongly correlated with neural activity 
within the brain’s default mode network, which has 
consistently shown deﬁ cient deactivation during task 
conditions in ADHD.59,60 For these reasons, spontaneous 
mind-wandering, detri mental to performance, has been 
proposed as a mechanism explaining some of the 
symptoms and impairments of ADHD.56
Several studies have reported increased spontaneous 
mind-wandering in adult ADHD.57,58 Adults with ADHD 
frequently report a distractible mental state with 
multiple unrelated thoughts that are constantly on the 
go and jump from one topic to another.61 Mind-
wandering is also a feature of other mental health 
disorders such as depressive ruminations or obsessional 
thoughts and might therefore lack speciﬁ city. However 
in ADHD, mind-wandering is characterised by 
unfocused, short-lived distractible thoughts with no 
pattern of repeated thoughts or abnormality of content.61
Our research62 showed that excessive mind-wandering 
was strongly correlated with ADHD symptoms, was a 
strong predictor of the diagnosis (sensitivity and 
speciﬁ city around 90% for case-control diﬀ erences), co-
varied with ADHD symptoms over a 6-month period, 
and was a better predictor of ADHD-related impairments 
than the inattentive and hyperactive-impulsive 
symptoms of ADHD. Excessive mind-wandering has 
several potential advantages as a clinical measure 
because it reﬂ ects a characteristic feature of the mental 
state reported by adults with ADHD and can be 
measured with rating scales56,58 and experience sampling 
in daily life63 or during sustained attention tasks.57
Executive function
Another aspect of ADHD is behaviour reﬂ ecting 
diﬃ  culties with executive functions such as inhibition 
and working memory. Whether dysfunctions of executive 
control reﬂ ect primary causal processes in ADHD is 
hotly debated. For example, cognitive test measures of 
executive control do not seem to predict long-term 
outcome in ADHD,35,64 are not strong predictors of 
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ADHD symptoms and impairments,65 and are neither 
necessary or suﬃ  cient to cause ADHD.66 Furthermore, 
the results of neuropsychological tests of executive 
functions do not correlate highly with behavioural rating 
scale measures of executive dysfunction.67 Nevertheless, 
at a behavioural level, ecologically valid descriptions of 
executive functions seem to show core behavioural 
problems that are strongly related to ADHD and respond 
well to drug treatments for ADHD.68–70 These clinically 
useful measures can be captured by the Brief Rating 
Inventory of Executive Function,71 which assesses 
organising, prioritising, and initiating work; focusing, 
sustaining, and shifting attention to tasks; regulating 
alertness, sustaining eﬀ ort, and processing speed; 
managing frustration and regulating emotions; using 
working memory and accessing recall; and monitoring 
and self-regulation of behaviour.
Course and outcome
Reasons for the persistence and desistence of ADHD into 
adulthood are not well understood, but are of considerable 
interest because they identify potential targets for early 
prevention and treatment. Factors inﬂ uencing course and 
outcome include general cognitive ability, severity of 
ADHD, causal factors (genes and environment), brain 
maturation and development, and the presence of co-
occurring mental health and neurodevelopmental 
disorders.33 Protective factors, such as exercise,72 might 
also have an important role. One study73 using an adoption 
at birth design to control for genetic inﬂ uences showed 
the possible role of hostile parenting using mothers’ 
reports of their own hostile behaviour towards their child. 
In this study, hostile parenting was both evoked in parents 
by having an infant with high levels of impulsive and 
overactive behaviour, but also acted as a causal inﬂ uence 
by increasing the later development of ADHD symptoms 
in children. Consistent with this ﬁ nding, another study 
found that high levels of parental criticism were associated 
with persistence of hyperactive behaviour between the 
ages of 7 and 13 years, even after controlling for 
oppositional deﬁ ant behaviour.74 Whether such parental 
eﬀ ects have any eﬀ ect on longer term outcomes in adults 
is not known.
The role of genetic inﬂ uences on stability and change in 
ADHD during adolescence and young adulthood has been 
investigated in population twin studies.75 The ﬁ ndings 
suggest a core set of genetic inﬂ uences that explain stability 
of the syndrome. However, in addition, new genetic eﬀ ects 
inﬂ uence risk for the disorder at diﬀ erent developmental 
stages, which suggests that maturational or developmental 
processes come into play, altering the interplay of 
neurobiological processes that lead to ADHD symptoms 
and impairments at diﬀ erent ages. At the clinical level, 
persistence of ADHD is associated with the severity of 
ADHD during childhood,76 and might be particularly high 
for people with high levels of both childhood inattentive 
and hyperactive-impulsive symptoms6 and for those with 
psychiatric comorbidity, exposure to adversity, and a family 
history of the disorder.76,77
There is also considerable interest in understanding 
the cognitive and neural deﬁ cits that mediate genetic 
risks on ADHD and might also be involved in persistence 
and remission of the disorder throughout development. 
One prominent hypothesis is that at the cognitive and 
neural level, measures of executive control and 
preparation-vigilance reﬂ ect interacting processes with 
diﬀ erent developmental courses that contribute to risk 
for ADHD. In a 6-year follow-up study using cognitive 
and electroencephalographic data of 110 young people 
with childhood DSM-IV combined type ADHD and 
169 controls, ADHD persisters diﬀ ered from remitters 
on preparation-vigilance measures but not on executive 
control measures.35 This ﬁ nding suggests that the 
preparation-vigilance measures might be markers of 
remission that improve alongside ADHD symptoms. As 
such, they might reﬂ ect malleable processes that can be 
targeted for prevention of long-term persistence of the 
disorder. High IQ also seemed to play a part in reducing 
risk for persistence of ADHD into young adulthood.
Adult-onset ADHD: a potential new trajectory 
for the disorder
ADHD has been traditionally conceptualised as a 
neurodevelopmental disorder and is included under this 
umbrella term in DSM-5.1 Although some disorders 
known to have a neurodevelopmental trajectory, such as 
schizophrenia, do not necessarily begin in childhood, 
ICD-10 clearly deﬁ nes that a neurodevelopmental 
disorder should have an onset during infancy or 
childhood. Thus, it is not surprising that age-of-onset 
during early childhood emerged as a key element in the 
deﬁ nition of ADHD. However, in the past four decades, 
experts behind diagnostic manuals have struggled with 
the lack of evidence to deﬁ ne an accurate age of onset 
beyond which symptoms should no longer be considered 
part of the ADHD syndrome. The age of onset deﬁ nitions 
applied were based solely on clinical wisdom; DSM-III 
introduced ADHD criterion B, requiring symptoms to be 
present before the age of 7 years, and DSM-IV-TR added 
that impairment must also be present by this same age. 
Under DSM-5 this deﬁ nition has been changed to several 
symptoms (with or without impairment) before the age 
of 12 years.
A report by Moﬃ  tt and colleagues10 presented new data 
challenging the notion that ADHD always begins in 
childhood. In a representative birth cohort including 
1037 subjects born in Dunedin, New Zealand, that were 
followed up to age 38 years with a retention rate of 
95%, prevalence rates of childhood and adulthood 
disorder were in accordance with estimates from 
previously published work (6% in childhood and 3·1% in 
adulthood). However, one ﬁ nding challenged the present 
conceptualisation of ADHD. The great majority of 
individuals qualifying for a diagnosis of adult ADHD 
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when the age-of-onset criterion was not applied (87%) did 
not have prior childhood ADHD. Importantly, the ADHD 
features in these adults did not seem to be accounted by 
their present comorbidities. Although both the child-
onset and adult-onset groups showed similar levels of 
impairments in adulthood, they seemed to diﬀ er with 
regard to symptoms of ADHD in adulthood, genetic 
inﬂ uences, and cognitive deﬁ cits.
Two other investigations in representative population 
samples from other regions (Brazil and the UK) found 
similar results. In the 1993 Pelotas Birth Cohort, 
5249 individuals were followed up to age 18–19 years, 
with 81·3% retention. Only 12·6% of young adults 
meeting the symptom and impairment criteria for 
ADHD as adults had the disorder in childhood.78 In the 
E-Risk Longitudinal Twin Study, a UK nationally 
representative birth cohort of 2232 twins born in England 
and Wales with 93% retention at age 18 years, ADHD 
diagnoses were assessed in childhood at ages 5, 7, 10, and 
12 years and in young adulthood at age 18 years. In 
individuals meeting ADHD criteria as adults, 67·5% did 
not meet the criteria for ADHD at any assessment at or 
before age 12 years. Individuals with late-onset ADHD 
showed similar ADHD symptoms and impairment 
compared with the persistent group.79
These ﬁ ndings suggest the existence of two 
phenotypically similar syndromes, with childhood onset 
and adulthood onset of ADHD symptoms and impair-
ments reﬂ ecting distinct developmental trajectories, 
potentially linked to diﬀ erent causal inﬂ uences and 
neural mechanisms. However, these are very recent 
ﬁ ndings and should be interpreted with caution. A third 
of the sample in the Dunedin study14 had conduct 
disorder as children and others showed signs of ADHD, 
so the adulthood-onset individuals were not free from 
earlier developmental problems during childhood. 
Attention also needs to be paid to measurement issues 
such as the use of self-ratings versus informant-ratings. 
In the Dunedin sample, both the childhood-onset and 
adulthood-onset groups had similar levels of adult 
ADHD symptoms according to informant reports, but 
not according to self-ratings, and similar levels of adult 
impairment. 14 This ﬁ nding is in line with the ADHD 
clinical follow-up studies that show greater diagnostic 
rates at follow-up when informant report, rather than 
self-report, is used as the primary source of information.35 
Further studies are therefore needed to clarify the 
proportion of adult cases that had subthreshold ADHD 
symptoms as children, as well as to provide an improved 
understanding of the clinical presentation of adults who 
had ADHD as children. As discussed previously, 
alternative measures such as sleep problems, excessive 
mind-wandering, emotional dysregulation, and executive 
function deﬁ cits could also be used to investigate the 
onset and developmental trajectory of ADHD. Because at 
present there are no clinical investigations of the 
adult-onset group, it is unknown whether they have 
similar or diﬀ erent neural underpinnings, response to 
treatments, and prognosis to the child-onset group.
ADHD, treatment, and comorbidity
One reason for the under-diagnosis of ADHD by adult 
mental health services is the nature of the clinical 
syndrome, which shares characteristics with other 
common adult mental health disorders. These include 
clinical features associated with adult ADHD that do not 
form part of the present DSM-5 or ICD-10 diagnostic 
criteria. Examples include poor concentration, 
distractibility, restlessness, over-talkativeness, sleep 
problems, irritability, impulsiveness, and low self-
esteem. However, in this regard, adult ADHD is no 
diﬀ erent from other common mental health disorders, 
many of which also share a similar set of overlapping 
symptoms. One clear distinction from most adult-onset 
disorders is the typical early onset and trait-like 
persistence of ADHD symptoms, which show what 
someone is usually like, rather than a change in 
premorbid mental state and episodic course. Because 
diagnostic symptom overlap is common for adult mental 
health disorders, this is unlikely to provide a full 
explanation for under-diagnosis of ADHD. A far more 
likely explanation is the present absence of awareness 
and training in the diagnosis and clinical management of 
ADHD in adults. Understanding of the similarities and 
diﬀ erences between adult ADHD and common mental 
health disorders such as anxiety, depression, bipolar 
disorder, personality disorder, substance misuse, and 
antisocial behaviour is therefore of great importance to 
clinical practice. Such disorders occur at increased rates 
in adult ADHD, when they could have a further eﬀ ect on 
long-term negative outcomes. Comorbid medical 
Panel 2: Symptoms and impairments of ADHD that can 
mimic other mental health disorders
Anxiety
• Worrying about performance deﬁ cits, excessive 
mind-wandering, feeling overwhelmed, feeling restless, 
avoidance of situations due to ADHD symptoms, such as 
diﬃ  culty waiting in queues or social situations requiring 
focused attention, and sleep problems linked to mental 
restlessness
Depression
• Unstable moods, impatience, irritability, poor 
concentration, sleep disturbance, low self-esteem
• Personality disorder (eg, borderline and antisocial)
• Chronic trait-like psychopathology linked to behavioural 
problems, emotional instability, impulsive behaviour, and 
poor social relationships
Bipolar disorder
• Restlessness, sleep disturbance, mood instability, 
ceaseless unfocused mental activity, and distractibility
574 www.thelancet.com/psychiatry   Vol 3   June 2016
Series
disorders are also a concern, with substantial evidence 
associating adult ADHD with obesity,80–82 and data linking 
the disorder to increased mortality, with the strongest 
single predictor being accident rates.83
Treatment
The high rate of undiagnosed ADHD in individuals with 
mental health problems is also a concern, given the 
availability of eﬀ ective drug and behavioural treatments 
for ADHD. Short-term, randomised, placebo-controlled 
trials of methylphenidate, d-amphetamine, and 
atomoxetine all show marked clinical eﬀ ects on ADHD 
symptoms, with standardised mean diﬀ erences between 
drug and placebo groups in the range of 0·4 to 0·7 in 
adult ADHD.84–87 These moderate-to-large clinical eﬀ ects 
compare favourably with the eﬀ ects of antidepressants 
on depression or antipsychotics on psychosis, for 
example, demonstrating the importance of appropriate 
targeting of ADHD treatments. Although both stimulant 
and non-stimulant drugs show clinically signiﬁ cant 
evidence for eﬃ  cacy, the stimulants are more eﬀ ective 
for the short durations of treatment which are 
characteristic of placebo-controlled studies.88 Evidence 
from controlled trials for the longer term beneﬁ ts of 
pharmacological treatments is largely absent, although a 
systematic review identiﬁ ed ﬁ ve randomised controlled 
trials and ten open-label extension studies with total 
follow-up of at least 24 weeks. All of the randomised 
trials reported that drug treatment was signiﬁ cantly 
better than placebo for treating ADHD in adults; the 
extension studies all reported that the favourable eﬀ ect of 
drugs seen in short-term trials was maintained during 
open-label follow-up.89 Pharmacoepidemiological studies 
using national registry data highlight the potential for 
very substantial long-term beneﬁ ts of treatment, not only 
on core ADHD symptoms, but also on serious co-
occurring problems. By comparison of periods of patients 
on and oﬀ  ADHD drug treatments, reductions in 
criminal convictions,90 transport accidents,91 substance 
misuse,92 and suicidal behaviour have been shown during 
periods on ADHD drug treatments.93
Psychosocial treatments including psychoeducation, 
cognitive behaviour therapy, and use of support groups, 
skills training, and coaching are thought to provide 
additional beneﬁ ts in the clinical management of 
ADHD,94,95 although studies are generally small and not 
well designed. Whether such approaches reduce the core 
symptoms of ADHD or rather improve secondary 
outcomes such as psychosocial and functional 
impairments is uncertain. A study of 419 adult patients 
with ADHD randomised to drug or placebo, with 
and without group psychotherapy, provides some 
clariﬁ cation.96 Short-term and 1-year eﬀ ects of drug 
treatment, but not psychotherapy, were seen on ADHD 
symptoms. Group psychotherapy was, however, 
associated with better 1-year outcome on a measure of 
overall clinical improvement (clinical global impression) 
when combined with the trial drug than when combined 
with placebo. This ﬁ nding is consistent with present 
guidelines that recommend psychological therapies are 
used as an adjunct to drug treatment in adult ADHD.97
Comorbidity
Despite the obvious contribution that ADHD makes to 
adult psychopathology and mental health problems, the 
similarities and diﬀ erences from other common mental 
health disorders and the eﬀ ects on treatment in comorbid 
cases are poorly understood. Three main groups should 
be considered. In the ﬁ rst group, ADHD might mimic 
other disorders, either because of overlap with core 
ADHD symptoms such as restlessness and poor 
concentration, or because of characteristic associated 
features of ADHD such as emotional instability, low self-
esteem, and sleep problems (panel 2). This group of 
individuals is important to identify because they are likely 
to respond to appropriate drug treatment for ADHD.
Panel 3: Key points and conclusions
Main ﬁ ndings
• Adult ADHD is a common mental health problem aﬀ ecting 2·5–3·4% of the adult 
population
• Undiagnosed ADHD is found in 10% or more of non-psychotic patients attending 
general adult, addiction, and prison mental health services
• Beyond the core symptoms of inattention and hyperactivity-impulsivity, ADHD is 
characterised by a wide range of mental health symptoms and impairments including 
initial sleep insomnia, excessive mind-wandering, restlessness, emotional instability, 
and behaviour showing diﬃ  culty with executive functions
• ADHD symptoms and impairments can mimic other common mental health 
disorders, leading to incorrect diagnoses and targeting of treatments
• The treatment response of adult ADHD symptoms and impairments to stimulants and 
atomoxetine shows these drugs to be among the most eﬀ ective pharmacological 
treatments for any mental health disorder
• Pharmacoepidemiological studies show reductions in criminal convictions, accidental 
injuries, substance misuse, and suicides after treatment of ADHD
Research recommendations
• Investigate the prevalence of undiagnosed ADHD in patients receiving treatments for 
mental health problems in primary care
• Investigate objective measures of ADHD symptoms, characterisation of the mental 
state and behavioural problems experienced by adults to improve recognition of 
ADHD in clinical practice
• Identify cognitive, neural, and genetic biomarkers to aid in diagnosis, clinical 
subtyping, and targeting or selection of treatments
• Investigate the eﬀ ectiveness of ADHD drug treatments on ADHD symptoms and 
impairments in the context of co-occurring personality, anxiety, and mood disorders
• Investigate the eﬀ ects of ADHD drug treatments on a wider range of outcomes 
including emotional instability, aggression, dysthymia, and sleep problems
• Investigate the eﬀ ectiveness of psychosocial treatments (including cognitive 
psychological education, cognitive behaviour therapy, and mindfulness-based 
interventions) on longer term outcomes in ADHD
• Investigate ADHD trajectories comparing clinical and population samples with special 
attention to potential adulthood-onset ADHD
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In the second group, neurodevelopmental traits and 
disorders are often seen to develop alongside ADHD. 
These include features of autism spectrum disorder, 
speciﬁ c reading diﬃ  culties (dyslexia), and develop mental 
coordination disorder (dyspraxia). Such neuro-
developmental comorbidities have a marked eﬀ ect on 
functional impairment but, unlike ADHD symptoms, do 
not respond to drug treatments for ADHD.
In the third group, co-occurring disorders might 
develop as a complication of ADHD. For example, 
children with ADHD are at greater risk for the 
development of substance misuse disorders, anxiety, 
depression, personality disorders (including antisocial 
and borderline), and criminal behaviour. The eﬀ ects of 
treating ADHD in this third group are not yet well 
researched and the present advice is based mainly on the 
experience of individual expert clinicians. For example, 
although we know that emotional dysregu lation often 
improves when treating adult ADHD, there is little 
information on the eﬀ ect of treating ADHD in comorbid 
ADHD patients with borderline or antisocial personality 
disorders. Nevertheless, pharmacoepidemiological 
studies90–93 suggest that treating ADHD can reduce 
associated criminal behavior, substance misuse, and 
suicide.
Another question is the part that ADHD plays in the 
maintenance of anxiety and depression and the eﬀ ects of 
treating ADHD in comorbid cases. The ubiquitous 
nature of emotional symptoms in adult mental health 
means that all individuals with a non-episodic form of 
emotional instability should be screened for ADHD, 
including those with chronic dysthymia, cyclothymia, 
and personality disorders. At present, such patients are 
often mistakenly diagnosed as having bipolar disorder, 
cyclothymia, or borderline personality disorder, even in 
cases where there are moderate-to-severe levels of ADHD 
symptoms and impairments.98
Conclusions
We conclude that ADHD should be recognised in the 
same way as other common adult mental health conditions, 
and that failure to recognise and treat ADHD is detrimental 
to the wellbeing of many patients seeking help for 
mental health problems. Although further research is 
needed to assess the eﬀ ects of ADHD drug treatments in 
ADHD complicated by comorbidities, eﬀ ective clinical 
management of ADHD should be an essential component 
of adult mental health care. A list of key points and 
research recommendations is provided in panel 3.
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